ADXS - Huge move is possible if conditions aline

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

SHORT INTEREST
235.59K 09/13/19

P/E Current
-0.02

P/E Ratio (with extraordinary items)
-0.13

Average Recommendation: BUY

Average Target Price: 5.00